Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With Ad-GMCAIX in Patients With Metastatic Renal Cell Carcinoma

Trial Profile

A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With Ad-GMCAIX in Patients With Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2019

At a glance

  • Drugs Ad-GMCAIX transduced dendritic cells (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 May 2019 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 10 Feb 2018 Results (n=9) presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top